Incyte shares results for ruxolitinib in the treatment of vitiligo at WCD

15 June 2019

Today, at the 24th World Congress of Dermatology (WCD) taking place in Milan, Italy, US biotech firm Incyte (Nasdaq: INCY) presented 24-week data from its Phase II study evaluating ruxolitinib cream as a treatment for adult patients with vitiligo.

Vitiligo is a chronic, immune-mediated skin condition that is estimated to affect between 2 and 3 million people in the USA and for which there is no known cure.

Overall, the study met its primary endpoint, demonstrating that significantly more patients treated with ruxolitinib cream for 24 weeks achieved at least 50% improvement from baseline in the facial vitiligo area severity index (F-VASI50) score compared to patients treated with a vehicle control (non-medicated cream). These results support the pivotal Phase III development of ruxolitinib cream in patients with vitiligo, for which preparations are now underway.+

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK